Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
Travel and Tropical Medicine
•
Primary Care
How do you approach management of patients who develop arthritis following asymptomatic or mild chikungunya infection?
Do you commonly see development of arthritis following asymptomatic or mild chikungunya infection?
Related Questions
Do you routinely recommend doxycycline for pregnant individuals with rickettsial diseases despite the historical concern for side effects in pregnancy?
What is your approach to the use of Paxlovid for patients with risk factors for severe Covid-19 infection but who have received SARS-CoV-2 vaccines in light of the EPIC-SR trial findings?
What is your preferred oral regime with duration for treatment of onychomycosis?
Is there a role for empiric scabies treatment in itchy patients without clear clinical signs of scabies?
How do you factor cerebrospinal fluid (CSF) antibody results when deciding on the diagnosis and treatment of racemose neurocysticercosis, given the uncertainties associated with CSF antibody testing?
Would you consider using long-acting injectable cabotegravir/rilpivirine for pregnant women with HIV?
In light of recent measles outbreaks in the US, would you recommend an MMR booster for an immunocompetent patients born before 1957?
Do you give additional pneumococcal vaccines after a dose of PCV20 in patients with asplenia?
What duration of antibiotic therapy do you use for a loculated parapneumonic effusion that does not meet criteria for empyema?
Do you routinely recommend transition to dual PO antibiotic coverage for strep species and MRSA, for patients with purulent cellulitis and in the absence of culture data?